精神分裂病(Schizophrenia):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Schizophrenia - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5664IDB
◆発行日:2014年10月30日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:351
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[精神分裂病(Schizophrenia):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における精神分裂病(Schizophrenia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・精神分裂病(Schizophrenia)の概要
・精神分裂病(Schizophrenia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・精神分裂病(Schizophrenia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・精神分裂病(Schizophrenia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・精神分裂病(Schizophrenia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Schizophrenia – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Schizophrenia – Pipeline Review, H2 2014’, provides an overview of the Schizophrenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
Introduction 6
Schizophrenia Overview 7
Therapeutics Development 8
Schizophrenia – Therapeutics under Development by Companies 10
Schizophrenia – Therapeutics under Investigation by Universities/Institutes 17
Schizophrenia – Pipeline Products Glance 18
Schizophrenia – Products under Development by Companies 22
Schizophrenia – Products under Investigation by Universities/Institutes 31
Schizophrenia – Companies Involved in Therapeutics Development 32
Schizophrenia – Therapeutics Assessment 112
Drug Profiles 126
Schizophrenia – Recent Pipeline Updates 282
Schizophrenia – Dormant Projects 319
Schizophrenia – Discontinued Products 323
Schizophrenia – Product Development Milestones 325
Appendix 335

[List of Tables]
Number of Products under Development for Schizophrenia, H2 2014 23
Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2014 24
Number of Products under Development by Companies, H2 2014 26
Number of Products under Development by Companies, H2 2014 (Contd..1) 27
Number of Products under Development by Companies, H2 2014 (Contd..2) 28
Number of Products under Development by Companies, H2 2014 (Contd..3) 29
Number of Products under Development by Companies, H2 2014 (Contd..4) 30
Number of Products under Development by Companies, H2 2014 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H2 2014 32
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Development, H2 2014 35
Comparative Analysis by Unknown Stage Development, H2 2014 36
Products under Development by Companies, H2 2014 37
Products under Development by Companies, H2 2014 (Contd..1) 38
Products under Development by Companies, H2 2014 (Contd..2) 39
Products under Development by Companies, H2 2014 (Contd..3) 40
Products under Development by Companies, H2 2014 (Contd..4) 41
Products under Development by Companies, H2 2014 (Contd..5) 42
Products under Development by Companies, H2 2014 (Contd..6) 43
Products under Development by Companies, H2 2014 (Contd..7) 44
Products under Development by Companies, H2 2014 (Contd..8) 45
Products under Investigation by Universities/Institutes, H2 2014 46
Schizophrenia - Pipeline by AbbVie Inc., H2 2014 47
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 48
Schizophrenia - Pipeline by Adamed Sp. z o.o., H2 2014 49
Schizophrenia - Pipeline by Addex Therapeutics Ltd, H2 2014 50
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2014 51
Schizophrenia - Pipeline by AGY Therapeutics, Inc., H2 2014 52
Schizophrenia - Pipeline by Alkermes Plc, H2 2014 53
Schizophrenia - Pipeline by Amgen Inc., H2 2014 54
Schizophrenia - Pipeline by Angita B.V., H2 2014 55
Schizophrenia - Pipeline by Ascendis Pharma A/S, H2 2014 56
Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2014 57
Schizophrenia - Pipeline by Athersys, Inc., H2 2014 58
Schizophrenia - Pipeline by BioCrea GmbH, H2 2014 59
Schizophrenia - Pipeline by Biotie Therapies Corp., H2 2014 60
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2014 61
Schizophrenia - Pipeline by BRAINco Biopharma, S.L., H2 2014 62
Schizophrenia - Pipeline by Cerecor Inc., H2 2014 63
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2014 64
Schizophrenia - Pipeline by Curemark, LLC, H2 2014 65
Schizophrenia - Pipeline by Delpor, Inc., H2 2014 66
Schizophrenia - Pipeline by Domain Therapeutics SA, H2 2014 67
Schizophrenia - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014 68
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2014 69
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2014 70
Schizophrenia - Pipeline by Eli Lilly and Company, H2 2014 71
Schizophrenia - Pipeline by Evotec AG, H2 2014 72
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 73
Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 74
Schizophrenia - Pipeline by Galenea Corp., H2 2014 75
Schizophrenia - Pipeline by GeNeuro SA, H2 2014 76
Schizophrenia - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 77
Schizophrenia - Pipeline by Gilead Sciences, Inc., H2 2014 78
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 79
Schizophrenia - Pipeline by GP Pharm, S.A., H2 2014 80
Schizophrenia - Pipeline by GW Pharmaceuticals plc, H2 2014 81
Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2014 82
Schizophrenia - Pipeline by Heptares Therapeutics Ltd., H2 2014 83
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 84
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 85
Schizophrenia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2014 86
Schizophrenia - Pipeline by Jiangsu Nhwa Pharma Corporation, H2 2014 87
Schizophrenia - Pipeline by Johnson & Johnson, H2 2014 88
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2014 89
Schizophrenia - Pipeline by KemPharm, Inc., H2 2014 90
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2014 91
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2014 92
Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2014 93
Schizophrenia - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 94
Schizophrenia - Pipeline by Merck & Co., Inc., H2 2014 95
Schizophrenia - Pipeline by Mithridion, Inc., H2 2014 96
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 97
Schizophrenia - Pipeline by Naurex, Inc., H2 2014 98
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2014 99
Schizophrenia - Pipeline by NeurOp, Inc, H2 2014 100
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 101
Schizophrenia - Pipeline by Novartis AG, H2 2014 102
Schizophrenia - Pipeline by Nuvo Research Inc., H2 2014 103
Schizophrenia - Pipeline by Omeros Corporation, H2 2014 104
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 105
Schizophrenia - Pipeline by Peptron, Inc., H2 2014 106
Schizophrenia - Pipeline by Pfizer Inc., H2 2014 107
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2014 108
Schizophrenia - Pipeline by Reckitt Benckiser Pharmaceutical, Inc., H2 2014 109
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 110
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2014 111
Schizophrenia - Pipeline by Rottapharm SpA, H2 2014 112
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 113
Schizophrenia - Pipeline by SK Chemicals Co., Ltd., H2 2014 114
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 115
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 116
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2014 117
Schizophrenia - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 118
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 119
Schizophrenia - Pipeline by Targacept, Inc., H2 2014 120
Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2014 121
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 122
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2014 123
Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H2 2014 124
Schizophrenia - Pipeline by Zogenix, Inc., H2 2014 125
Schizophrenia - Pipeline by Zysis Limited, H2 2014 126
Assessment by Monotherapy Products, H2 2014 127
Assessment by Combination Products, H2 2014 128
Number of Products by Stage and Target, H2 2014 130
Number of Products by Stage and Mechanism of Action, H2 2014 134
Number of Products by Stage and Route of Administration, H2 2014 138
Number of Products by Stage and Molecule Type, H2 2014 140
Schizophrenia Therapeutics - Recent Pipeline Updates, H2 2014 297
Schizophrenia - Dormant Projects, H2 2014 334
Schizophrenia - Discontinued Products, H2 2014 338

[List of Figures]
Number of Products under Development for Schizophrenia, H2 2014 23
Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2014 24
Number of Products under Development by Companies, H2 2014 25
Number of Products under Investigation by Universities/Institutes, H2 2014 32
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Products, H2 2014 35
Assessment by Monotherapy Products, H2 2014 127
Number of Products by Top 10 Targets, H2 2014 129
Number of Products by Stage and Top 10 Targets, H2 2014 129
Number of Products by Top 10 Mechanism of Actions, H2 2014 133
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 133
Number of Products by Top 10 Routes of Administration, H2 2014 137
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 137
Number of Products by Top 10 Molecule Types, H2 2014 139
Number of Products by Stage and Top 10 Molecule Types, H2 2014 139

*** 掲載企業 ***

AbbVie Inc.
Acadia Pharmaceuticals Inc.
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Aestus Therapeutics, Inc.
AGY Therapeutics, Inc.
Alkermes Plc
Amgen Inc.
Angita B.V.
Ascendis Pharma A/S
Astellas Pharma Inc.
Athersys, Inc.
BioCrea GmbH
Biotie Therapies Corp.
Boehringer Ingelheim GmbH
BRAINco Biopharma, S.L.
Cerecor Inc.
Critical Pharmaceuticals Limited
Curemark, LLC
Delpor, Inc.
Domain Therapeutics SA
Dong Wha Pharma Co., Ltd.
Echo Pharmaceuticals B.V.
Egis Gyogyszergyar Nyrt
Eli Lilly and Company
Evotec AG
F. Hoffmann-La Roche Ltd.
FORUM Pharmaceuticals Inc.
Galenea Corp.
GeNeuro SA
Genovate Biotechnology Co., LTD.
Gilead Sciences, Inc.
Glenmark Pharmaceuticals Ltd.
GP Pharm, S.A.
GW Pharmaceuticals plc
H. Lundbeck A/S
Heptares Therapeutics Ltd.
Hisamitsu Pharmaceutical Co., Inc.
Intra-Cellular Therapies, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Nhwa Pharma Corporation
Johnson & Johnson
Karuna Pharmaceuticals Inc.
KemPharm, Inc.
Laboratorios Farmaceuticos Rovi, S.A.
Lead Discovery Center GmbH
Luye Pharma Group Ltd.
MarcoPolo Pharmaceuticals SA
Merck & Co., Inc.
Mithridion, Inc.
Mitsubishi Tanabe Pharma Corporation
Naurex, Inc.
Neurocrine Biosciences, Inc.
NeurOp, Inc
Newron Pharmaceuticals S.p.A.
Novartis AG
Nuvo Research Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Peptron, Inc.
Pfizer Inc.
Promentis Pharmaceuticals, Inc.
Reckitt Benckiser Pharmaceutical, Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
Rottapharm SpA
SK Biopharmaceuticals Co., Ltd.
SK Chemicals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc.
Suven Life Sciences Ltd.
Taisho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Targacept, Inc.
Tetra Discovery Partners LLC
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.
XTL Biopharmaceuticals Ltd.
Zogenix, Inc.
Zysis Limited

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5664IDB )"精神分裂病(Schizophrenia):治療薬開発パイプライン動向(2014年下半期版)" (英文:Schizophrenia - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。